

1 Colorimetric Detection of SARS-CoV-2 Using Plasmonic Biosensors 2 and Smartphones

3 Elsa M. Materón,* Faustino R. Gómez, Mariana B. Almeida, Flavio M. Shimizu, Ademar Wong,
4 Kelcilene B. R. Teodoro, Filipe S. R. Silva, Manoel J. A. Lima, Monara Kaelle S. C. Angelim,
5 Matias E. Melendez, Nelson Porras, Pedro M. Vieira, Daniel S. Correa, Emanuel Carrilho,
6 Osvaldo N. Oliveira, Jr., Ricardo B. Azevedo, and Débora Goncalves



Cite This: <https://doi.org/10.1021/acsami.2c15407>



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

7 **ABSTRACT:** Low-cost, instrument-free colorimetric tests were
8 developed to detect SARS-CoV-2 using plasmonic biosensors with
9 Au nanoparticles functionalized with polyclonal antibodies (f-
10 AuNPs). Intense color changes were noted with the naked eye
11 owing to plasmon coupling when f-AuNPs form clusters on the
12 virus, with high sensitivity and a detection limit of 0.28 PFU mL^{-1}
13 (PFU stands for plaque-forming units) in human saliva. Plasmon
14 coupling was corroborated with computer simulations using the
15 finite-difference time-domain (FDTD) method. The strategies
16 based on preparing plasmonic biosensors with f-AuNPs are robust
17 to permit SARS-CoV-2 detection via dynamic light scattering and
18 UV-vis spectroscopy without interference from other viruses, such
19 as influenza and dengue viruses. The diagnosis was made with a
20 smartphone app after processing the images collected from the smartphone camera, measuring the concentration of SARS-CoV-2.
21 Both image processing and machine learning algorithms were found to provide COVID-19 diagnosis with 100% accuracy for saliva
22 samples. In subsidiary experiments, we observed that the biosensor could be used to detect the virus in river waters without
23 pretreatment. With fast responses and requiring small sample amounts (only $20 \mu\text{L}$), these colorimetric tests can be deployed in any
24 location within the point-of-care diagnosis paradigm for epidemiological control.

25 **KEYWORDS:** gold nanoparticles, localized surface plasmon resonance, plasmonic coupling, SARS-CoV-2, point-of-care, machine learning,
26 image processing, portable sensor



1. INTRODUCTION

27 Mass testing for viral diseases remains relevant given the
28 persistence of contamination with the severe acute respiratory
29 syndrome coronavirus 2 (SARS-CoV-2 virus). Most diagnostic
30 tests require cheaper detection methods than prevailing
31 molecular techniques, such as reverse transcription-quantitative
32 polymerase chain reaction (RT-qPCR), isothermal amplifica-
33 tion-based methods, and CRISPR-based diagnostics.¹ Antigen-
34 based detection (antigen test) has become commonplace in
35 lateral flow immunoassays (LFI) or immunostrips,² but it
36 achieves less sensitive responses than the reverse-transcription
37 polymerase chain reaction (RT-PCR).³ Current tests employ
38 mostly blood and nasopharyngeal samples, which are
39 uncomfortable for many patients. Less invasive sample
40 collection is preferable, as saliva sampling is accessible to
41 self-collect, particularly in fragile and vulnerable patient
42 populations.⁴ The pathogen levels in saliva are comparable to
43 those in nasopharyngeal samples, with the advantage of a small

44 variability across trials.⁵ In addition, the costs of collection and
45 storage are also reduced.

46 Challenges are often found in processing and avoiding
47 degradation in saliva, which has hampered diagnostic tools.⁶
48 Furthermore, effective detection of SARS-CoV-2 in saliva
49 requires high sensitivity because of its enzymes that may
50 destabilize nucleic acid and inhibit proteases.^{7,8} For SARS-
51 CoV-2, most infectious saliva and cough specimens have virus
52 loads near 10^6 PFU mL^{-1} (PFU stands for plaque-forming
53 units), indicating that 10–100 μL droplets could deposit 10^4 –
54 10^5 PFU of infectious material.^{9–11} The minimal contagious
55 dose in humans ranges from 1 to 5 PFU.¹²

Received: August 26, 2022

Accepted: November 8, 2022

Although SARS-CoV-2 infection occurs predominantly through the respiratory tract, the entry of virus into the bloodstream compromises other organs, and viral RNA has been detected in the feces of infected individuals, even after respiratory symptoms have diminished.¹³ Likewise, SARS-CoV-2 has been detected for prolonged periods in wastewater treatment plants¹⁴ and river waters.¹⁵ Excretions through feces occur due to the viral infection into the gastrointestinal tract via the angiotensin-converting enzyme 2 (ACE2) receptor expressed by epithelial cells in the gastrointestinal system,¹⁶ and even *via* urine and saliva. Hence, virus particles can be dragged to treatment plants and may not be cleared during water treatment.¹⁶ Therefore, detecting SARS-CoV-2 is not only relevant for diagnosis in humans but also for verifying possible contamination of water resources.

Pathogens and other biomarkers can be detected with several principles, including electrical,¹⁷ electrochemical,¹⁸ optical,¹⁹ and thermoplasmonic chips.²⁰ Colorimetric tests are preferred in many scenarios owing to the simplicity of the analysis.²¹ Nevertheless, it is challenging if the detection processes must yield significant color changes. For colorimetric tests, the use of nanoparticles is noteworthy,²² including Ag nanoparticles,²³ Au nanoparticles (AuNPs),²⁴ quantum dots,²⁵ magnetic nanoparticles,²⁶ and Au nanorods,²⁷ which have been used to detect SARS-CoV-2 virus or IgG antibodies with localized surface plasmon resonance (LSPR) and surface-enhanced Raman spectroscopy (SERS). AuNPs are known for their chemical stability, easy modification, and bioconjugation of biomolecules, such as DNA, antibody, enzymes, and other proteins.²⁸ For example, immunogenic B cell epitopes can be attached to AuNPs to detect COVID-19-specific IgG where the optical properties of AuNPs are exploited.²⁹ Also, colloidal Au can be prepared with controllable sizes using the well-known citrate reduction method.³⁰ AuNPs show a high-surface density of free electrons, from which LSPR has emerged.³¹ LSPR is produced by the collective oscillation of surface electrons induced by visible light, manifested by an extinction band in the visible region. It is relevant that LSPR depends on the refractive index of the surrounding medium and the interparticle distance, providing the basis for colorimetric plasmonic sensors.^{32–34} In such colorimetric sensors, observation with the naked eye can be done with changes in the liquid phase within 5 min, *i.e.*, one may distinguish between positive and negative results.³⁵ AuNPs have been employed in detecting viruses such as Zika (ZIKV), Ebola (EBOV), Influenza A virus (H1N1), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).³¹ Antibodies coupled to AuNPs can bind to the viral antigen leading to agglomeration of NPs, thus shifting its color from red to blue.²⁴

Herein, low-cost, instrument-free, fast-response plasmonic biosensors were designed to detect SARS-CoV-2 in saliva and river water without sample pretreatment. Detection was primarily based on naked-eye colorimetry. Meanwhile, more detailed considerations of the detection processes were studied using UV-vis spectroscopy. For naked-eye colorimetry, we used a free smartphone application to process the images acquired with the smartphone camera, thus allowing instant results similar to other examples described in the literature (see Table S1 in the Supporting Information). The mechanisms responsible for the colloidal nanoparticle clustering around the virus, then allowing their detection with high sensitivity, are investigated for the first time using theoretical simulations with

the finite-difference time-domain (FDTD) method. The most relevant contribution of this work is associated with the fast detection of SARS-CoV-2 without requiring instruments, with the high accuracy warranted by treating images with machine learning algorithms.

2. MATERIALS AND METHODS

Gold(III) chloride trihydrate (HAuCl₄·3H₂O, ≥99.9% purity), 11-mercaptoundecanoic acid (MUA, ≥95%), sodium citrate dihydrate (≥99%), *N*-(3-dimethylaminopropyl)-*N*'-ethylcarbodiimide hydrochloride (EDC, ≥98%), *N*-hydroxysuccinimide (NHS, 98%), bovine serum albumin (BSA, ≥98%), poly(ethylene glycol) methyl ether thiol, average Mn 6000 (PEG-SH), and phosphate-buffered saline powder (pH 7.4) (P3813–10PAK) were purchased from Sigma-Aldrich. Recombinant anti-SARS-CoV-2 Spike glycoprotein S1 antibody (ab273073), recombinant human coronavirus SARS-CoV-2 Spike glycoproteins S1 (Active) (ab273068), and RBD (Active) (ab273065) were acquired from Abcam. Polyclonal antibody against the N-terminal domain of the SARS-CoV-2 Spike protein from rabbits was kindly provided by Virology and Microscopy Laboratory, Universidade de Brasília, Brazil. H1N1 California (OPPA01974) and Dengue envelope-3 (DENV, OPPA02454) proteins were acquired from Aviva Systems Biology. Gold seed particles were prepared using a modified Turkevich synthesis³⁶ by adding gold chloride via sodium citrate reduction. The growth of Au nanoparticles (AuNPs) occurred after mixing two solutions, *viz.* 2.2 × 10⁻³ mol L⁻¹ citrate and 25 × 10⁻³ mol L⁻¹ HAuCl₄, seven times with a 30-min break.¹ The solution containing AuNPs was cooled by adding 50 mL of ultrapure water. The solution was kept at 4 °C in the dark for further work.

2.1. Transmission Electron Microscopy (TEM) and Field-Emission Scanning Electron Microscopy (SEM-FEG). TEM images of AuNPs were collected using a Philips CM200 Transmission Electron microscope designed to obtain high-resolution images with a Super Twin polar piece using an electron beam energy of 25 keV. TEM sample grids were prepared by depositing 10 mL of AuNP suspension onto carbon-coated copper grids, followed by air-drying at room temperature. The average diameter was determined using ImageJ software. SEM-FEG images were obtained using a JEOL JSM-7500F microscope with operating software PC-SEM equipped with secondary and back-scattered electron detectors. Chemical analysis by energy-dispersive spectroscopy (EDS) was performed using an UltraDry detector from Thermo Scientific with NSS 2.3 operating software. Colloidal AuNPs were washed twice, diluted in ultrapure water, and deposited onto glassy carbon supports for later drying at room temperature.

2.2. UV/Vis Spectroscopy (UV/VIS) and Dynamic Light Scattering (DLS) Measurements. The UV-vis spectra were collected using a spectrophotometer (Thermo Scientific, Nanodrop 2000/2000c) from 200–800 nm using a 1-cm quartz cuvette. The nanoparticles were washed twice in 5 × 10⁻³ mol L⁻¹ phosphate-buffered saline (PBS) at pH 7.4, and 20 μL of AuNP solutions were diluted in 980 μL of 5 × 10⁻³ mol L⁻¹ PBS at pH 7.4. All AuNP suspensions were analyzed by dynamic light scattering (DLS) using a Nano ZS Malvern Zetasizer using the same washing procedure described before for the UV-vis measurements.

2.3. Attenuated Total Reflectance (ATR). The attenuated total reflectance spectra were recorded from 4300 to 600 cm⁻¹ using a Bruker Vertex 70 FTIR spectrometer equipped with an attenuated total reflectance (ATR) accessory. The measurements were performed using a blank citrate/AuNP solution. For each measurement, the AuNPs were washed twice in ultrapure water to remove excess PBS and reduce its signals. The samples were prepared by depositing 20 μL of the AuNP suspension onto the crystal, and measurements were acquired for the colloidal samples at a resolution of 4 cm⁻¹ with 64 co-added scans/spectrum.

2.4. Inactivation of SARS-CoV-2 Virus and Sample Preparation. The inactivated virus samples used in our studies were obtained from HIAE-02 SARS-CoV-2/SP02/human/2020/BRA (GenBank: 185

186 616 MT126808.1) isolated from the second confirmed case in Brazil.
187 The viral stocks of SARS-CoV-2 were propagated in Vero cell lines,
188 and the supernatant was harvested at 2–3 days post-infection. Viral
189 titers were determined by plaque assays on Vero cells, in which the
190 number of plaque-forming units (PFU) represents the viral quantity.
191 Vero CCL-81 cells were cultivated in Dulbecco's modified Eagle's
192 medium (DMEM) (10% fetal bovine serum (FBS), 1% penicillin–
193 streptomycin) and incubated at 37 °C with a 5% CO₂ atmosphere. As
194 a control, a conditioned medium of Vero cells was used after being
195 treated in the same way but without the virus. Virus inactivation was
196 performed using a CL1000 UVP crosslinker under UV irradiation in a
197 microbiological safety cabinet, following Patterson et al.³⁷ The virus
198 stock was added (1500 μL) on 100 mm culture dishes and placed
199 without its lid 6 cm below the UV bulbs. With this procedure, the
200 viruses are inactivated by UV irradiation, and their protein structure is
201 preserved.^{38,39} Inactivated SARS-CoV-2 was obtained from the
202 Institute of Biology, University of Campinas (Brazil). Subsequently,
203 a stock solution of the virus was prepared with 10 μL diluted in 990
204 μL 5.0 × 10⁻³ mol L⁻¹ PBS at pH 7.4, 7000 PFU.

205 **2.5. Modification of Colloidal Au Nanoparticles.** Twenty-four
206 microtubes with 1 mL of AuNPs each were used with the following
207 procedure: 1.0 mL of nanoparticles was added to 56.7 μL of 1.9 ×
208 10⁻³ mol L⁻¹ MUA (dissolved in ethanol) under stirring at 28 °C for
209 2 h. Then, 55 μL of 2.0 × 10⁻⁴ mol L⁻¹ PEG-SH was added to the
210 solution of AuNPs/MUA (dissolved in ultrapure water) for another 2
211 h under stirring at 28 °C.⁴⁰ Volumes of 19 μL of 2.5 × 10⁻³ mol L⁻¹
212 EDC and 35 μL of 1.0 × 10⁻² mol L⁻¹ NHS in ultrapure water were
213 added to the AuNPs/MUA/PEG-SH solution, which was stirred at 28
214 °C for 20 min. The mixture was then centrifuged at 7300 rpm for 20
215 min at 15 °C. The AuNPs were resuspended in 5 × 10⁻³ mol L⁻¹ PBS
216 at pH 7.4 with SARS-CoV-2 spike polyclonal antibody (ab) added to
217 obtain a final concentration of 2 μg mL⁻¹ (AuNPs/MUA/PEG-ab),
218 followed by incubation overnight at 28 °C. The AuNPs/MUA/PEG-
219 ab solution was centrifuged for 20 min at 7300 rpm at 15 °C. The
220 supernatant was discarded, and the sediment was resuspended in 200
221 μL of PBS and 300 μL of 0.5% BSA at a final percentage of 0.2%. The
222 f-AuNP (AuNPs/MUA/PEG-ab/BSA) solution was centrifuged,
223 resuspended twice to remove antibodies in excess, and stored at 4 °C.

2.6. Detection of SARS-CoV-2 in Saliva and Spiked River Samples.

225 **2.6.1. Synthetic and Human Saliva.** Synthetic saliva was
226 prepared with 0.228 g of CaCl₂·2H₂O, 0.061 g of MgCl₂·6H₂O, 1.017
227 g of NaCl, 0.504 g of K₂CO₃, 0.272 g of Na₂HPO₄·12H₂O, and 0.273
228 g of NaH₂PO₄·H₂O.⁴¹ All reagents were diluted in 1 L and used only
229 for comparison with human saliva with a negative Covid test.⁴¹ Then,
230 a volume of 20 μL of artificial saliva was diluted in 960 μL of 5.0 ×
231 10⁻³ mol L⁻¹ PBS and 20 μL of the f-AuNP solution was added. This
232 solution was compared with the human saliva of healthy donors
233 without symptoms and negative tests, obtaining comparable results. In
234 samples with saliva from a donor tested negative, different
235 concentrations of the inactivated virus were spiked to the samples.
236 In the proof-of-concept experiments, a similar procedure was
237 performed using eleven samples of human saliva: five from individuals
238 without symptoms (S₁–S₅), three from volunteers with no symptoms
239 and negative PCR tests (S_p, S_m, and S_B), and three from volunteers
240 with positive Covid tests (C₁, C₂, and C₃). The saliva donors followed
241 the protocols required by pharmacies for tests, *viz.*, they should not
242 eat, drink coffee, or brush their teeth for 2 h prior to saliva collection.
243 Also, they should not use lipstick, gloss, or menthol products.⁵
244 Samples were collected in 2 mL tubes and measured immediately.⁴²

245 **2.6.2. River Samples.** River water samples were collected from the
246 Gregorio River (GPS coordinate: 21°59'11.0" S 47°52'52.1" W)
247 located in the city of São Carlos-SP (Brazil). A volume of 50 μL of a
248 river sample was diluted in 930 μL of 5.0 × 10⁻³ mol L⁻¹ PBS to
249 which 20 μL of the f-AuNP solution was added.⁴³ Then, different
250 concentrations of the inactivated virus were spiked into the river water
251 samples.

252 **2.7. Quantification of Proteins on AuNPs.** The AuNP–
253 antibody solutions were centrifuged at 7300 rpm for 20 min, the
254 supernatant was removed, and the remaining pellet was resuspended
255 with 5 × 10⁻³ mol L⁻¹ PBS. This procedure was repeated three times

to remove unreacted EDS and NHS, with only AuNP–antibody 256
complexes left. The washed solution was diluted at 1:5 and 1:10 vol/ 257
vol, and the antibody concentration was calculated using the 258
bicinchoninic acid (BCA) protein assay according to the manufac- 259
turer's protocol (Pierce). The absorbance was measured for diluted 260
solutions at 562 nm using a NanoDrop 2000c Spectrophotometer in 261
the cuvette mode, and the concentration of the bound antibody was 262
calculated by multiplying the concentration by the dilution factor. 263
Mean and standard deviations for the concentration were calculated 264
considering both samples. The BCA assay showed an average 265
antibody concentration of 9.3 ± 0.4 μg mL⁻¹ (n = 2) on the surface of 266
AuNPs. This value should be considered with care once the number 267
of antibodies may be overestimated in the BCA protein assay and 268
enzyme-linked immunosorbent assay (ELISA),⁴⁴ it serves to confirm 269
modification for nanoparticles coated with antibodies.⁴⁵ 270

2.8. Smartphone-Based Detection and Statistical Analysis.

271 Smartphone-based sensing was conducted by getting images directly 272
from the microcentrifuge tube using a Samsung smartphone (Galaxy 273
J8, 16 megapixels camera, with Android 10). The RGB (red, green, 274
blue) mean values were taken as an analytical signal in real-time 275
through the free application (App) Color Grab (Loomatix, version 276
3.9.2), available for Android systems. For acquiring the digital images 277
in microtubes, we used a built-in polylactic acid (PLA) support 278
fabricated with a three-dimensional (3D) printer (Crealty Ender-3) 279
with the following dimensions: height of 5 cm and a 10-cm distance 280
between the smartphone camera and the microtube (see Figure S1 in 281
the Supporting Information). A printable copy of the file (.stl) is 282
available in the Supporting Information (Figure S1). The images were 283
analyzed with the software ImageJ using a 50-pixel circular region, and 284
the RGB (red, green, blue) values were used as the analytical response 285
(X). The best linear relationship to X is shown in eq 1, where the 286
letters B and R denote the blue channel and red channel, respectively, 287
and the subscripts "s" and "b" correspond to the values of the sample 288
or standard and the analytical blank, respectively. The blue channel 289
(B_s) and red channel (R_s) are the values of the sample, while the blank 290
of the blue channel is B_b and the blank of the red channel is R_b (See 291
Figure S1). 292

$$X = \frac{B_s}{R_s} - \frac{B_b}{R_b} \quad (1)$$

The limit of detection (LOD) of the assay was calculated based on the 294
standard deviation of the blank or the control sample (SD_b) and the 295
angular coefficient (b—slope) obtained from the analytical curve 296
(ICH 2005),⁴⁶ according to eq 2. 297

$$\text{LOD} = \frac{3.3 \times \text{SD}_b}{b} \quad (2)$$

The experiments were conducted in triplicate, and the relevant data 299
were expressed as the mean ± SD. The statistical analyses were 300
performed using Origin 9.0 and Statistica 13.5.0.17 (TIBCO) 301
software. 302

303 **2.9. FDTD Simulations.** The absorption spectra and electro-
magnetic field distribution for isolated AuNPs and aggregates were
calculated using a software package, FDTD Solutions by Ansys
Lumerical Solutions. The simulation region was a 2 μm cube
surrounded by a perfectly matched layer (PML) filled with water
(refractive index RI = 1.33). The mesh size was set to 0.5 nm in all
spatial dimensions. The AuNPs were simulated as homogenous
spheres of 31 nm diameter, and the dielectric function of Au was
adopted from the experimental data obtained by Johnson and
Christy.⁴⁷ The molecular linkers and antibodies anchored to the Au
surface were simulated as a dielectric shell with a refractive index of
1.4 and 1.5 nm thick. The virus was simulated as a homogeneous
dielectric sphere with a 100-nm diameter and a refractive index of
1.54, surrounded by a 10-nm thick dielectric shell with a refractive
index of 1.46.⁴⁸ Functionalized AuNP (f-AuNP) clusters were
randomly placed on the virus surface to simulate the aggregate
system. The algorithm for generating the clusters first added a 319
functionalized NP onto the virus surface from a randomized position. 320




Figure 1. (A) Schematic design for modification of AuNPs, throughout the various steps. (B) UV-vis spectra for the distinct steps in the bioconjugation (AuNPs after addition of: step 1 MUA, step 2 PEG-SH, step 3 EDC/NHS, step 4 antibody, and step 5 BSA). (C) ATR spectra for AuNPs coated with MUA, then MUA-PEG and MUA-PEG-anti-SARS-CoV-2. (D) ζ -potential at each step of AuNP bioconjugation and in the presence of $3.2 \mu\text{g mL}^{-1}$ S protein of SARS-CoV-2 virus.

321 Subsequently, a second NP was located randomly around the initial
322 particle. The cluster was grown until a specified number of NPs was
323 reached. The cluster formation randomly achieved the interparticle
324 distance between 1 and 2 nm. A total-field scattered field (TFSF)
325 source with a wavelength ranging from 350 to 850 nm was used to
326 illuminate the systems. The incident plane wave was x -polarized, and
327 the propagation direction was set along the minus z -axis. The electric
328 field strength of the incident irradiation was set at 1.0 V m^{-1} . A 3D
329 frequency-domain field profile monitor and a group analysis (both
330 inside the TSFS source) were used to record the electric field and
331 calculate the absorption cross-section, respectively. All of the
332 absorption cross-section spectra are reported as a dimensionless
333 Mie efficiency calculated by dividing the optical cross-section by
334 $N\pi R^2$, where R is the radius of the NPs and N is the number of NPs in
335 a cluster.⁴⁹

3. RESULTS AND DISCUSSION

336 **3.1. Bioconjugation and Images of AuNPs.** The FEG-
337 SEM and TEM images show spherical AuNPs with an average
338 diameter of 31 nm (Figure S2A,B in the Supporting
339 Information). The high purity of AuNPs was confirmed with
340 a strong signal of elemental Au in Figure S2C (EDS analysis),
341 with stability in the pH range between 3.0 and 8.0 in $5.0 \times$
342 $10^{-3} \text{ mol L}^{-1}$ PBS, as indicated in Figure S2D. The AuNPs
343 were functionalized by covalent coupling of antibodies using a
344 mercaptoundecanoic acid binder (MUA), following the
345 procedure depicted in Figure 1A. The whole procedure was
346 monitored using UV-vis spectroscopy and ζ -potential
347 measurements. MUA was bound covalently onto AuNPs
348 through its thiol groups to the Au surface; its quaternary
349 ammonium counterion adsorbed on the Stern layer provided
350 stability against aggregation.⁵⁰ AuNPs coated with MUA had a
351 35-nm diameter, which confirmed an increase in shell
352 thickness. MUA coating is not expected to be homogeneous
353 but on patches according to dissipative particle dynamics
354 simulations.⁵¹ Figure 1B shows the plasmonic peak of
355 monodisperse AuNPs at 524 nm shifted to 526 nm for

AuNPs-MUA,⁵² with the increased absorbance after MUA
356 modification occurring due to aggregation of AuNPs. PEG-SH
357 occupies the remaining free AuNP surface, exhibiting a radial
358 conformation since the thiol group has a stronger affinity for
359 the AuNP surface than PEG chains, thus removing these from
360 the NP surface.⁵¹ A decrease in absorbance was observed upon
361 adding PEG⁵³ due to aggregation of polydisperse PEG-
362 AuNPs⁵⁴ and after activating terminal carboxylic acid head-
363 groups by EDC/NHS at pH ~ 6.0 . The pK_a of EDC is 6.0, and
364 that of MUA on Au is 4.5–6.0. Hence, deprotonation of 11-
365 MUA and protonation of EDC seem to be important in the
366 activation reaction.⁵⁵ The formation of nanoensembles can
367 cause a decrease in absorbance due to their activating ability.⁵⁶
368 EDC/NHS binding has the advantage of providing a stable,
369 biocompatible, covalent bond.⁵⁷ The activation mechanism of
370 carboxyl groups mediated by EDC/NHS involves the
371 formation of an adduct, an *O*-acylisourea derivative, between
372 EDC and the carboxyl group of MUA.⁵⁸ The *O*-acylurea
373 adduct reacts with a primary amine and produces the desired
374 peptide coupling, but it has a low reaction rate. Hence, NHS
375 provides a more stable intermediate to react with a primary
376 amine forming an amide bond.⁵⁹ Then, a nucleophilic attack
377 by NHS may occur to form an *N*-succinimidyl ester, releasing a
378 soluble urea derivative as a by-product.⁵⁸
379

The incorporation of antibodies increased the absorbance
380 intensity significantly due to an increased effect on the
381 hydrodynamic-layer thickness of the AuNPs and changed their
382 refractive index after conjugation.⁶⁰ In subsidiary experiments,
383 we observed that efficient plasmonic biosensors can be
384 obtained with either monoclonal or rabbit polyclonal antibod-
385 ies. The results in detecting inactivated viruses via DLS are
386 shown in Figure S3. We have therefore employed the
387 polyclonal antibody in the subsequent studies. The remaining
388 active sites after the antibody adsorption were blocked by BSA
389 addition, which caused a decrease in absorbance. The 390




Figure 2. TEM micrographs of f-AuNPs after exposure to 250 and 6000 PFU mL⁻¹ of SARS-CoV-2.




Figure 3. Spectral absorption efficiency for clusters with (A) one, (B) two, and (C) three f-AuNPs. (D) and (G) show the electric field amplitude at the resonant frequency for Conf_1 and Conf_2 in (A), respectively. (E) and (H) show the electric field amplitude at the resonant frequency for Conf_1 and Conf_4 in (B), respectively. (F) and (I) show the electric field amplitude at the wavelength resonant $\lambda = 545$ nm and $\lambda = 642$ nm for Conf_3 in (C).

391 attachment of antibodies was confirmed with the ATR spectra
 392 in Figure 1C, featuring O–H and C=O bands assigned to
 393 stretching vibrations of –COOH groups of Au–MUA⁶¹ at
 394 3261 and 1433 cm⁻¹, which are slightly altered after the

addition of PEG. The 3261 cm⁻¹ band was increased, while the
 1433 cm⁻¹ band almost disappeared after bioconjugation. The
 functionalization of AuNPs affected their ζ -potential in Figure
 1D, ranging from –43.96 mV for AuNPs to –35.32 mV after




Figure 4. (A) UV-vis spectra for solutions containing inactivated SARS-CoV-2 virus at concentrations 0, 7, 144, 250, 418, 520, 636, 750, 860, 971, 1073, 1172, 1268, 1360, 1781, 2142, 2459, 2736, and 2980 PFU mL⁻¹. As the concentration increases, there is a change from a reddish to bluish color in the f-AuNP solution, which is indicated in the inset photos. We used two colors (red and blue) in the spectra to indicate this gradual change. (B) Averaged spectral absorption efficiency for various f-AuNPs in the aggregate clusters was obtained with FDTD simulations. The spectra are also shown in two colors to indicate the color change. The caption avg corresponds to the average spectral absorption efficiency of five different configurations in the FDTD simulations.

399 MUA coating. The ζ -potential further varied by attaching PEG
400 (-38.72 mV), antibodies (-31.64 mV), and BSA (-33.68
401 mV). When $2.0 \mu\text{g mL}^{-1}$ SARS-CoV-2 S protein was added,
402 the ζ -potential decreased (in modulus) to -30.86 mV, as
403 expected from the literature.⁶² It is worth noting that BSA
404 improves the stability of AuNPs functionalized with PEG and
405 increases the ζ -potential,⁶³ which decreases when f-AuNPs
406 interact with the S protein of the SARS-CoV-2 virus.

407 TEM images of functionalized AuNPs (f-AuNPs) exposed to
408 SARS-CoV-2 at 250 and 6000 PFU concentrations are shown
409 in Figure 2. For both concentrations, clusters of different
410 numbers of f-AuNPs are formed on the virus surface and may
411 not cover the entire surface. For 250 PFU, AuNP clusters
412 recover the viral particles as expected,⁶⁴ and several
413 neighboring NPs agglomerate around it. The hydrodynamic
414 radius of the AuNPs increases with the SARS-CoV-2
415 concentration,⁶⁵ as indicated in DLS measurements in Figure
416 S3 in the Supporting Information. At 6000 PFU, some virus
417 particles are not covered by AuNPs.

418 **3.2. Simulations.** The phenomenon of f-AuNP aggregation
419 and clustering on the virus surface forms the basis of the
420 colorimetric-based sensor proposed in this work. It is,
421 therefore, useful to model such interactions with FDTD
422 simulations, which allow one to analyze the light absorption
423 properties of the f-AuNP-virus system as a function of
424 interparticle distances and cluster sizes. Figure 3 shows the
425 absorption efficiency spectra for aggregates with different
426 numbers of f-AuNPs (1–3), including the spectrum for an
427 isolated f-AuNP. Since the f-AuNPs are randomly located, a
428 statistical study was necessary for which we employed five
429 different AuNP configurations for a given cluster size, denoted
430 with distinct captions (conf_1-conf_5). The caption avg
431 corresponds to the average of these configurations. We plot
432 the electric field amplitude at the resonant frequency for some
433 configurations, with the same color map scale for some cluster
434 sizes. The FDTD results in Figure 3A indicate that an isolated
435 f-AuNP exhibits a strong LSPR around ~ 525 nm, in agreement
436 with the experimental spectrum in Figure 1B. The near-field
437 electric distribution for the modified-AuNP at the plasmon
438 resonance wavelength is shown in Figure S4 in the Supporting
439 Information. Due to the LSPR effect, the electric field was
440 enhanced around the f-AuNP, with the enhancement locally
441 reaching up to 4.5 times the intensity of incident light.

442 On the other hand, when f-AuNP are aggregated on the
443 virus surface, the spectrum of different configurations differs in
444 absorption amplitude and frequency for maximum absorption
445 from the isolated f-AuNP. In particular, as the f-AuNP and
446 virus align with the polarization direction of the source (x -
447 axis), the absorption amplitude, resonance frequency, and
448 electromagnetic field in the region of contact increase (Figure
449 3D,G). Compared with the far-field response of an isolated f-
450 AuNP, the changes are minimal, which is not helpful for
451 colorimetric sensors. In contrast to the single nanoparticle-
452 virus system, a new set of plasmonic modes are seen at larger
453 wavelengths, with a significant enhancement of the electric
454 field (especially in the gap between nanoparticles, *i.e.*, at the
455 “hotspots”), for some dimer- or trimer-virus configurations
456 (Figure 3B,C,E,F,H,I). These new bands arise from the strong
457 near-field coupling of LSPRs of individual particles, which can
458 be understood in terms of the plasmon hybridization theory.⁶⁶
459 From the field profiles, it could be inferred that plasmonic
460 coupling decreases with an increase in interparticle separation.
461 It is also possible to infer a strong dependence of the
462 plasmonic coupling upon the relative orientations of the cluster
463 concerning the polarization direction of the source. The more
464 aligned the f-AuNPs with the incident electric field, the
465 stronger the plasmonic coupling is. The absorption efficiency
466 spectra for aggregates with nanoparticle numbers 4, 8, 16, and
467 32 are shown in Figure S5. As the size of the cluster increases
468 for each random cluster configuration, there is an increase in
469 the probability of matching the axis in a hotspot with the
470 polarization light, which leads to the optical absorption spectrum
471 to shift toward larger wavelengths, with the appearance of new
472 plasmonic bands. Since these variations are associated with
473 intense color variations of the solutions, the theoretical results
474 highlight the importance of aggregation and cluster formation
475 of f-AuNPs on the virus surface in Figure 2. Hence, the larger
476 the cluster, the easier it is to detect the virus.

477 **3.3. Spectrophotometric and Naked-Eye Detection.** A
478 quantitative determination of inactivated SARS-CoV-2 and the
479 Spike protein was performed with absorbance spectroscopy in
480 artificial saliva samples. Figure S6A shows a decrease in the
481 absorbance of the plasmonic band centered at 526 nm with
482 increasing concentration. This decrease was expected because
483 polyclonal antibodies may bind to the S protein at multiple
484 epitopes so that the S protein serves as a crosslinker to
485 aggregate f-AuNPs, thus quenching the plasmonic band.




Figure 5. (A) IDMAP visualization of data from the response with the plasmonic biosensor for SARS-CoV-2 virus (concentrations between 7 PFU and 2981 PFU) diluted in 0.5 mmol L^{-1} PBS (pH 7.4). (B) IDMAP visualization of the data for human saliva of healthy volunteers (with no symptoms, but not tested) (S_1 – S_5), S_p and S_m (volunteers with no symptoms and who were tested negative for Covid-19), S_B Saliva diluted in 0.5 mmol L^{-1} PBS (pH 7.4), human saliva from volunteers tested negative (S) contaminated with 250, 1000, and 5000 PFU and positive PCR test of virus-carrying patients (C_1 , C_2 , and C_3). (C) ExMatrix representation using the RF model (9 Decision Trees—8 logic rules) for the binary problem, with YES or NO classes for positive and negative SARS-COV-2 patients, respectively.

486 Indeed, quenching of f-AuNPs was reported for other
 487 analytes,⁶⁷ depending on the type of coupling, interparticle
 488 spacing, and local dielectric environment.⁶⁷ No other band is
 489 formed since the Spike protein is small compared to the virus.
 490 The protein reacts with the antibody on the f-AuNP surface,
 491 and no clusters of f-AuNPs are formed. Hence, there are only
 492 refractive index changes, which can only be detected at high
 493 concentrations of SARS-CoV-2.⁶⁸ In contrast, for the
 494 inactivated SARS-CoV-2, Figure 4A shows that the plasmonic
 495 band is redshifted with the concentration, and another band
 496 appears at 636 nm. This new band results from the large
 497 clusters of f-AuNPs on the virus surface, as discussed in Section
 498 3.2, and leads to a change in the solution color from red (w/o
 499 virus) to blue (w/ virus). This is represented by changing the
 500 color of the spectra in Figure 4A. The limit of detection
 501 (LOD) was calculated from the parameters extracted by fitting
 502 the experimental results using the Langmuir–Hill model for
 503 the inactivated virus (Figure S7). LOD is 0.28 PFU mL^{-1} by
 504 taking the peak shift ($\Delta\lambda$) from normalized spectra and 0.29
 505 PFU mL^{-1} using the absorbance ratio at 526 and 636 nm
 506 (A_{526}/A_{636}).

507 Figure 4B shows theoretical spectra that resemble the
 508 experimental spectra in Figure 4A. To interpret the spectra, we
 509 recall the theoretical calculations in Figure 3 (and Figure S5 in

the Supporting Information), where the average absorption 510
 efficiency was calculated for clusters with 1, 2, 3, 4, 8, 16, and 511
 32 NPs and for the case in which the virus surface is entirely 512
 covered by f-AuNPs (*i.e.*, with 69 NPs). Comparing with the 513
 theoretical results in Figure 4B, we infer that the absorption 514
 band centered at 526 nm is mainly related to the absorption 515
 response of isolated AuNPs, which are dominant at low 516
 concentrations. The plasmonic response of the single nano- 517
 particle–virus system and the transversal plasmonic couplings 518
 in larger aggregates could also contribute to the appearance of 519
 this band. On the other hand, as the virus concentration 520
 increases, the f-AuNPs agglomerate on the virus surface to 521
 form clusters of different sizes. Since these clusters exhibit 522
 different optical responses, the plasmonic band becomes 523
 broader. It should be noted that the predicted bands with 524
 FDTD for complete virus coverage with f-AuNPs are not 525
 observed experimentally. Therefore, the probability of 526
 experimentally observing total virus coverage is small, 527
 consistent with the SEM images in Figure 2. 528

Despite the evident changes in color, choosing one specific 529
 wavelength to collect absorbance values from hundreds of 530
 absorbance spectra is difficult. To facilitate interpretation by 531
 the reader, we used a multidimensional projection technique, 532
 referred to as Interactive Document Mapping (IDMAP).⁶⁹ 533




Figure 6. (A) Photo shows the colorimetric response of the plasmonic biosensor for different concentrations of inactivated SARS-CoV-2 in 0.5 mmol L⁻¹ PBS, pH 7.4. (B) Schematic design for SARS-CoV-2 virus detection with a smartphone camera. (C) Violin plots for the colorimetric results from the SARS-CoV-2 analysis in saliva samples using the biosensor.

534 The FastMap method was used to reduce the 350 dimensions,
 535 *i.e.*, the UV–vis spectrum (400–750 nm), to only 2
 536 dimensions.⁶⁹ Hence, one converts each spectrum into a
 537 single-colored dot on the visualization map. Evident discrim-
 538 ination of the samples with distinct concentrations of
 539 inactivated virus, from 0 to 2981 PFU mL⁻¹, is obtained in
 540 Figure 5A, with a silhouette coefficient of 0.97 (which varies
 541 from -1 to 1).⁶⁹ To demonstrate the applicability of the f-
 542 AuNPs biosensor, we analyzed several saliva samples (in
 543 triplicate, *n* = 3) obtained from 10 volunteers as follows: five
 544 healthy volunteers (*S*₁–*S*₅) who were not tested; two
 545 volunteers with negative PCR tests (*S*_p and *S*_M), three
 546 volunteers tested positive for Covid-19 (*C*₁, *C*₂, and *C*₃).
 547 Also, the saliva samples of one of the volunteers who tested
 548 negative were diluted in 0.5 mmol L⁻¹ PBS (samples *S*_p) and
 549 then spiked with the inactivated virus at 250, 1000, and 5000
 550 PFU mL⁻¹. There were, therefore, 14 distinct types of samples
 551 whose spectra were projected in the IDMAP plot in Figure 5B.
 552 There is a clear separation of samples from healthy individuals
 553 on the left-upper side of the map (reddish dots), while the
 554 saliva samples from contaminated patients and healthy
 555 individuals spiked with standards of 250 to 5000 PFU mL⁻¹
 556 are located on the bottom of the map (bluish dots). Diagnosis
 557 of COVID-19 could also be made with the data from the saliva
 558 samples using supervised machine learning within the
 559 multidimensional calibration space concept.⁷⁰ An accuracy of
 560 100% was obtained in the binary classification (YES or NO for
 561 the virus) when the random forest (RF) algorithm was applied.
 562 The results are illustrated in the Explainable Matrix (ExMatrix)
 563 representation⁷⁰ in Figure 5C. The space had five dimensions,
 564 *i.e.*, light absorption at five frequencies had to be used in the
 565 eight rules of the RF algorithm. It is also significant that the
 566 first three dimensions were already responsible for 98% of the
 567 information.

568 **3.4. Interferents and Other Applications.** To assess the
 569 selectivity of the proposed plasmonic biosensor, proteins of
 570 different viruses were chosen as interferents, including SARS,

H1N1, and Dengue, at concentrations of 2×10^{-6} and 2×10^{-4}
 $10^{-4} \mu\text{g mL}^{-1}$ in PBS. These data were projected in Figure S8
 (Supporting Information) with SARS-CoV-2 in concentrations
 between 7 and 2981 PFU mL⁻¹, with the interferents being
 grouped around the data for low concentrations of the SARS-
 CoV-2 virus. High (0.4–5.6 $\mu\text{g mL}^{-1}$) and low concentrations
 (2×10^{-6} and $2 \times 10^{-4} \mu\text{g mL}^{-1}$) of Spike protein were also
 projected with interferents to demonstrate how different the
 proteins are from the viruses since they are placed in opposite
 directions as depicted in the IDMAP plot of Figure S9.

The impact of the exposure of virus particles from biological
 aerosols on sewage workers, communities, and wildlife should
 be investigated, along with initiatives to reduce the load of
 viruses in water reservoirs.¹⁶ This type of monitoring requires
 simple methods for detecting and quantifying SARS-CoV-2 in
 waters (and wastewaters), mainly to identify possible routes of
 SARS-CoV-2 into water bodies.⁷¹ This work demonstrates that
 the plasmonic biosensor can be applied in complex matrices.
 We tested river water (without a precleaning step) samples
 spiked with inactivated SARS-CoV-2 virus at five concen-
 trations (7, 250, 1000, 5000, and 6000 PFU mL⁻¹). The
 separation in Figure S10 for these data indicates that the
 plasmonic biosensor can also be employed in environmental
 monitoring for the presence of SARS-CoV-2.

3.5. Smartphone-Based Detection. A rapid, inexpensive,
 and label-free method for real-time detection of SARS-CoV-2
 was developed based on the surface plasmon resonance of f-
 AuNPs utilizing a smartphone application, Color Grab (see
 Figure S11 in the Supporting Information). A redshift in the
 absorbance of colloidal AuNPs is observed with saliva samples
 in the absence of the virus; when the inactivated virus is added,
 as shown in Figure 6A, a color change from red to blue is
 observed, as expected from the literature.^{31,40} Figure S12
 shows a blue color predominating for high PFU concentrations
 (*i.e.*, >2000 PFU mL⁻¹). These color differences can be
 distinguished with the naked eye by humans with normal
 trichromatic vision who can combine in their brain three

Table 1. Analytical Performance of the Optical Biosensor Using the Digital Image Analysis of the Ratio of Blue-to-Red (B/R) Channels in Different Sample Media

assay	medium	analytical measurement	linear range ($n = 5$, PFU mL ⁻¹)	intercept	slope	R ²	LOD
A	buffer	B/R	7–2000	−0.124	0.169	0.997	2.2
B	saliva	B/R	250–5000	−0.411	0.170	0.903	2.0
C	river	B/R	7–2000	−0.098	0.156	0.941	3.4

independent wavelengths, corresponding to red, green, and blue, to generate the color observed.⁷² However, the perception of color differences is not the same in all individuals, and many users may suffer from problems such as color blindness or color vision deficiency.⁷² Furthermore, these devices may be affected by environmental conditions (e.g., poor ambient lighting or flashing lights of emergency vehicles) in addition to natural, person-to-person perceptual differences. These limitations can be mitigated with image processing,⁷² as we have done here. We employed the RGB model, where each component of the color space may vary between 0 and 255 in images obtained under controlled ambient light with a simple box for photography and accessories to hold a smartphone (Figure S11). Figure 6B shows an illustration of the result displayed on a smartphone. The results from the color analysis on the digital images are given in the violin plot⁷³ of Figure 6C, featuring data from artificial saliva and saliva of healthy donors and patients.

Using color Grab and RGB values from the images taken with a smartphone camera, the absorbance ratio (blue/red) was calculated to quantify the concentration of SARS-CoV-2 virus as in ref 73. Since the application Color Grab is unavailable on some smartphones, we tested a different approach for digital image analysis with a free, open-source image processing software (ImageJ) to obtain the RGB values. One-way analysis of variance (ANOVA) followed by Tukey's test performed at low, medium, and high SARS-CoV-2 concentrations showed no significant differences ($p < 0.05$) between the images treated with a smartphone app and ImageJ. The detection limit was estimated as described by the International Union of Pure and Applied Chemistry (IUPAC).¹⁸ Table 1 shows the analytical parameters for three types of assays. The first one was performed in PBS with increasing concentrations of inactivated virus (assay A), leading to a LOD of 2.2 PFU mL⁻¹. In Assay B, the saliva samples from a volunteer with a negative PCR test were spiked with the inactivated virus at concentrations from 250 to 5000 PFU mL⁻¹. The LOD obtained from the digital image analysis was 2.0 PFU mL⁻¹. Assay C was conducted with samples collected from river water samples without a precleaning step. These samples were spiked with inactivated virus from 7 to 2000 PFU mL⁻¹ (see Figure S14 in the Supporting Information), and a LOD of 3.4 PFU mL⁻¹ was obtained for the digital image analysis. It is also worth mentioning that the images from human saliva samples spiked with H1N1 and dengue virus proteins could not be distinguished from those of healthy volunteers.

4. CONCLUSIONS

The approach of functionalizing Au nanoparticles (f-AuNPs) with polyclonal antibodies for SARS-CoV-2 was exploited in plasmonic biosensors to detect inactivated viruses with a colorimetric, instrument-free technique. The sensitivity is sufficient for diagnosis using saliva, with a limit of detection (LOD) of 2.2 and 2.0 PFU mL⁻¹ in assays with the inactivated

virus in PBS solutions and the saliva of a volunteer, respectively. We found that the high sensitivity is related to the processes involving the cluster formation of f-AuNPs around the virus. As indicated in the FDTD computer simulations, a significant color change is only observed when large clusters are formed. The suitability of the biosensor with f-AuNPs was confirmed with other detection principles, including UV-vis spectroscopy and dynamic light scattering. The plasmonic biosensor specific for SARS-CoV-2 was demonstrated in experiments with potential interferents, such as the proteins from SARS, H1N1, and Dengue viruses. Detection of the UV-inactivated SARS-CoV-2 in human saliva and river waters could be done within 5 min, as the liquid and solutions changed color from red to purple, with possible observation with naked eyes. This color change was exploited in a smartphone application where images taken with the smartphone camera were processed with Color Grab and ImageJ software. With the latter, it was possible to determine whether the sample was positive for SARS-CoV-2 and to estimate the virus concentration. The app may also incorporate image processing combined with machine learning to provide COVID-19 diagnosis, whose accuracy in the tests performed with the colorimetric assay was 100%. These results indicate that plasmonic biosensors, like those developed here, can be used for low-cost COVID-19 diagnosis and monitoring within the point-of-care paradigm and in poor or remote locations.

Moreover, it is critical to consider the probability of environmental contamination and spread through wastewater and river waters. For example, places with poor sanitation and inadequate treatment can lead to nonpoint contamination of surface waters with SARS-CoV-2. For this reason, investigating methodologies that allow the detection of pathogens in places with little infrastructure is essential. Our proposed biosensor is promising for using river water samples without any previous treatment.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acsami.2c15407>.

Microscopy analysis; DLS results; FDTD simulation; UV-vis spectra; IDMAP plot; pictures of colorimetric samples and device; and comparison of main contributions from the literature (PDF)

■ AUTHOR INFORMATION

Corresponding Author

Elsa M. Materón – São Carlos Institute of Physics, University of São Paulo, 13560-970 São Carlos, SP, Brazil; Instituto de Química de São Carlos, Universidade de São Paulo, 13566-590 São Carlos, SP, Brazil; orcid.org/0000-0002-3382-1193; Email: elsa_materon@yahoo.com

711 **Authors**

- 712 **Faustino R. Gómez** – São Carlos Institute of Physics,
713 University of São Paulo, 13560-970 São Carlos, SP, Brazil;
714 orcid.org/0000-0001-5758-0489
- 715 **Mariana B. Almeida** – Instituto de Química de São Carlos,
716 Universidade de São Paulo, 13566-590 São Carlos, SP,
717 Brazil; Instituto Nacional de Ciência e Tecnologia de
718 Bioanalítica-INCTBio, 13083-970 Campinas, SP, Brazil
- 719 **Flavio M. Shimizu** – Department of Applied Physics, “Gleb
720 Wataghin” Institute of Physics (IFGW), University of
721 Campinas (UNICAMP), 13083-859 Campinas, SP, Brazil;
722 orcid.org/0000-0002-4833-9893
- 723 **Ademar Wong** – Department of Chemistry, Federal University
724 of São Carlos (UFSCar), 13560-970 São Carlos, São Paulo,
725 Brazil
- 726 **Kelcilene B. R. Teodoro** – Nanotechnology National
727 Laboratory for Agriculture, Embrapa Instrumentation,
728 13560-970 São Carlos, SP, Brazil; orcid.org/0000-0003-4337-4849
- 729 **Filipe S. R. Silva** – Instituto de Química de São Carlos,
730 Universidade de São Paulo, 13566-590 São Carlos, SP,
731 Brazil; orcid.org/0000-0003-3085-8510
- 732 **Manoel J. A. Lima** – Instituto de Química de São Carlos,
733 Universidade de São Paulo, 13566-590 São Carlos, SP,
734 Brazil
- 735 **Monara Kaelle S. C. Angelim** – Department of Genetics
736 Evolution, Microbiology, and Immunology, Institute of
737 Biology, University of Campinas, 13083-970 Campinas, SP,
738 Brazil
- 739 **Matias E. Melendez** – Molecular Carcinogenesis Program,
740 National Cancer Institute, 20231-050 Rio de Janeiro, RJ,
741 Brazil; orcid.org/0000-0002-0643-6185
- 742 **Nelson Porras** – Physics Department, del Valle University, AA
743 25360 Cali, Colombia
- 744 **Pedro M. Vieira** – Department of Genetics Evolution,
745 Microbiology, and Immunology, Institute of Biology,
746 University of Campinas, 13083-970 Campinas, SP, Brazil
- 747 **Daniel S. Correa** – Nanotechnology National Laboratory for
748 Agriculture, Embrapa Instrumentation, 13560-970 São
749 Carlos, SP, Brazil; orcid.org/0000-0002-5592-0627
- 750 **Emanuel Carrilho** – Instituto de Química de São Carlos,
751 Universidade de São Paulo, 13566-590 São Carlos, SP,
752 Brazil; Instituto Nacional de Ciência e Tecnologia de
753 Bioanalítica-INCTBio, 13083-970 Campinas, SP, Brazil;
754 orcid.org/0000-0001-7351-8220
- 755 **Oswaldo N. Oliveira, Jr.** – São Carlos Institute of Physics,
756 University of São Paulo, 13560-970 São Carlos, SP, Brazil;
757 orcid.org/0000-0002-5399-5860
- 758 **Ricardo B. Azevedo** – Laboratory of Nanobiotechnology,
759 Department of Genetics and Morphology, Institute of
760 Biological Sciences, University of Brasília, 70910-900
761 Brasília, DF, Brazil
- 762 **Débora Goncalves** – São Carlos Institute of Physics,
763 University of São Paulo, 13560-970 São Carlos, SP, Brazil

765 Complete contact information is available at:
766 <https://pubs.acs.org/10.1021/acsami.2c15407>

767 **Author Contributions**

768 E.M.M.: Methodology, investigation, acquisition of photos
769 using a smartphone, synthesis of gold nanoparticles, validation,
770 conceptualization, project administration, data analysis, visual-
771 ization, writing for the original draft, and editing. F.R.G.:
772 Conceptualization, acquisition of photos with a smartphone,

simulations, visualization, writing for the original draft, and 773
editing. M.B.A.: Discussion of results of the images, visual- 774
ization, and writing for the original draft. F.M.S.: artificial saliva 775
methodology, discussion of results, data curation, visualization, 776
writing for the original draft, and editing. A.W.: Synthesis of 777
gold nanoparticles, collecting river samples, discussion of 778
results, writing for the original draft, and editing. K.B.R.T. and 779
D.S.C.: Investigation with DLS analysis, validation, and writing 780
for the original draft. F.S.R.S.: protein quantification, 781
acquisition of photos with a smartphone, validation, and 782
writing for the original draft. M.J.A.L.: Discussion of image 783
results, 3D printed box design and printing, and writing for the 784
original draft. M.K.S.C.A., M.E.M., and P.M.V.: inactivation of 785
virus and discussion of results and writing for the original draft. 786
N.P.: funding, computer simulations, and discussion of 787
theoretical simulations. E.C.: Supervision, funding, saliva 788
samples, writing for the original draft, and editing. O.N.O.Jr., 789
R.B.A., and D.G.: Supervision, funding, project administration, 790
writing for the original draft, and editing. All of the authors 791
discussed the results and edited/reviewed the manuscript. 792

793 **Notes**

794 The authors declare no competing financial interest. 794
795 The authors declare that they have no known competing 795
796 financial interests or personal relationships that could have 796
797 appeared to influence the work reported in this paper. 797

798 **ACKNOWLEDGMENTS**

799 This work was supported by CAPES (Finance code 001), 799
800 INEO, CNPq (402816/2020-0, 304431/2020-6, 311757/
2019-7, 465389/2014-7, 115857/2022-2), and FAPESP 801
802 (2018/22214-6, 2014/50867-3, 2019/19235-4, 2021/08387-
8, 2017/03879-4), Edital de projetos integrados de pesquisa 803
em áreas estratégicas (PIPAE). 804

805 **REFERENCES**

- 806 (1) Malekshahi, A.; Khanizadeh, S.; Fallahi, S.; Talei, G.; Birjandi, 806
807 M.; Hajizadeh, F. Diagnostic Power of One-Step and Two-Step RT-
808 QPCR Methods to SARS-CoV-2 Detection. *BMC Infect. Dis.* **2022**,
22, No. 505. 809
- 810 (2) Bruzzzone, B.; De Pace, V.; Caligiuri, P.; Ricucci, V.; Guarona, G.;
811 Pennati, B. M.; Boccotti, S.; Orsi, A.; Domnich, A.; Da Rin, G.; Icardi,
812 G. Comparative Diagnostic Performance of Rapid Antigen Detection
813 Tests for COVID-19 in a Hospital Setting. *Int. J. Infect. Dis.* **2021**, *107*,
215–218. 814
- 815 (3) Kendall, E. A.; Arinaminpathy, N.; Sacks, J. A.; Manabe, Y. C.;
816 Dittrich, S.; Schumacher, S. G.; Dowdy, D. W. Antigen-Based Rapid
817 Diagnostic Testing or Alternatives for Diagnosis of Symptomatic
818 COVID-19: A Simulation-Based Net Benefit Analysis. *Epidemiology*
819 **2021**, *32*, 811–819.
- 820 (4) Warsi, I.; Khurshid, Z.; Shazam, H.; Umer, M. F.; Imran, E.;
821 Khan, M. O.; Slowey, P. D.; Goodson, J. M. Saliva Exhibits High
822 Sensitivity and Specificity for the Detection of SARS-COV-2. *Diseases*
823 **2021**, *9*, 38.
- 824 (5) Wyllie, A. L.; Fournier, J.; Casanovas-Massana, A.; Campbell,
825 M.; Tokuyama, M.; Vijayakumar, P.; Warren, J. L.; Geng, B.;
826 Muenker, M. C.; Moore, A. J.; Vogels, C. B. F.; Petrone, M. E.; Ott, I.
827 M.; Lu, P.; Venkataraman, A.; Lu-Culligan, A.; Klein, J.; Earnest, R.;
828 Simonov, M.; Datta, R.; Handoko, R.; Naushad, N.; Swanan, L. R.;
829 Valdez, J.; White, E. B.; Lapidus, S.; Kalinich, C. C.; Jiang, X.; Kim, D.
830 J.; Kudo, E.; Linehan, M.; Mao, T.; Moriyama, M.; Oh, J. E.; Park, A.;
831 Silva, J.; Song, E.; Takahashi, T.; Taura, M.; Weizman, O.-E.; Wong,
832 P.; Yang, Y.; Bermejo, S.; Odio, C. D.; Omer, S. B.; Dela Cruz, C. S.;
833 Farhadian, S.; Martinello, R. A.; Iwasaki, A.; Grubaugh, N. D.; Ko, A.
834 I. Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-
835 CoV-2. *N. Engl. J. Med.* **2020**, *383*, 1283–1286.

- 836 (6) Bulfoni, M.; Sozio, E.; Marcon, B.; De Martino, M.; Cesselli, D.;
837 De Carlo, C.; Martinella, R.; Migotti, A.; Vania, E.; Zanus-Fortes, A.;
838 De Piero, J.; Nencioni, E.; Tascini, C.; Isola, M.; Curcio, F. Validation
839 of a Saliva-Based Test for the Molecular Diagnosis of SARS-CoV-2
840 Infection. *Dis. Markers* **2022**, *2022*, 1–8.
- 841 (7) de Oliveira, C. M.; Brochi, L.; Scarpelli, L. C.; Lopes, A. C. W.;
842 Levi, J. E. SARS-CoV-2 Saliva Testing Is a Useful Tool for Covid-19
843 Diagnosis. *J. Virol. Methods* **2021**, *296*, 114241.
- 844 (8) Bustos-García, B.; Garza-Manero, S.; Cano-Dominguez, N.;
845 Lopez-Sanchez, D. M.; Salgado-Montes de Oca, G.; Salgado-Aguayo,
846 A.; Recillas-Targa, F.; Avila-Rios, S.; Valdes, V. J. Development and
847 Testing of a Low-Cost Inactivation Buffer That Allows for Direct
848 SARS-CoV-2 Detection in Saliva. *Vaccines* **2022**, *10*, 730.
- 849 (9) Lin, Y. C.; Malott, R. J.; Ward, L.; Kiplagat, L.; Pabbaraju, K.;
850 Gill, K.; Berenger, B. M.; Hu, J.; Fonseca, K.; Noyce, R. S.; Louie, T.;
851 Evans, D. H.; Conly, J. M. Detection and Quantification of Infectious
852 Severe Acute Respiratory Coronavirus-2 in Diverse Clinical and
853 Environmental Samples. *Sci. Rep.* **2022**, *12*, No. 5418.
- 854 (10) Sender, R.; Bar-On, Y. M.; Gleizer, S.; Bernshtein, B.; Flamholz,
855 A.; Phillips, R.; Milo, R. The Total Number and Mass of SARS-CoV-2
856 Virions. *Proc. Natl. Acad. Sci. U.S.A.* **2021**, *118*, No. e2024815118.
- 857 (11) Johnson, T. J.; Nishida, R. T.; Sonpar, A. P.; Lin, Y. C. J.;
858 Watson, K. A.; Smith, S. W.; Conly, J. M.; Evans, D. H.; Olfert, J. S.
859 Viral Load of SARS-CoV-2 in Droplets and Bioaerosols Directly
860 Captured during Breathing, Speaking and Coughing. *Sci. Rep.* **2022**,
861 *12*, No. 3484.
- 862 (12) Bradburne, A. F.; Bynoe, M. L.; Tyrrell, D. A. J. Effects of a
863 “New” Human Respiratory Virus in Volunteers. *Br. Med. J.* **1967**, *3*,
864 767–769.
- 865 (13) Tran, H. N.; Le, G. T.; Nguyen, D. T.; Juang, R.; Rinklebe, J.;
866 Bhatnagar, A.; Lima, E. C.; Iqbal, H. M. N.; Sarmah, A. K.; Chao, H.-
867 P. SARS-CoV-2 Coronavirus in Water and Wastewater: A Critical
868 Review about Presence and Concern. *Environ. Res.* **2021**, *193*,
869 No. 110265.
- 870 (14) de Oliveira, L. C.; Torres-Franco, A. F.; Lopes, B. C.; da Silva
871 Santos, B. S. A.; Costa, E. A.; Costa, M. S.; Reis, M. T. P.; Melo, M.
872 C.; Polizzi, R. B.; Teixeira, M. M.; Mota, C. R. Viability of SARS-CoV-
873 2 in River Water and Wastewater at Different Temperatures and
874 Solids Content. *Water Res.* **2021**, *195*, No. 117002.
- 875 (15) Haramoto, E.; Malla, B.; Thakali, O.; Kitajima, M. First
876 Environmental Surveillance for the Presence of SARS-CoV-2 RNA in
877 Wastewater and River Water in Japan. *Sci. Total Environ.* **2020**, *737*,
878 No. 140405.
- 879 (16) Bivins, A.; Greaves, J.; Fischer, R.; Yinda, K. C.; Ahmed, W.;
880 Kitajima, M.; Munster, V. J.; Bibby, K. Persistence of SARS-CoV-2 in
881 Water and Wastewater. *Environ. Sci. Technol. Lett.* **2020**, *7*, 937–942.
- 882 (17) Rashed, M. Z.; Kopechek, J. A.; Priddy, M. C.; Hamorsky, K.
883 T.; Palmer, K. E.; Mittal, N.; Valdez, J.; Flynn, J.; Williams, S. J. Rapid
884 Detection of SARS-CoV-2 Antibodies Using Electrochemical
885 Impedance-Based Detector. *Biosens. Bioelectron.* **2021**, *171*,
886 No. 112709.
- 887 (18) Fabiani, L.; Saroglia, M.; Galatà, G.; De Santis, R.; Fillo, S.;
888 Luca, V.; Faggioni, G.; D’Amore, N.; Regalbutto, E.; Salvatori, P.;
889 Terova, G.; Moscone, D.; Lista, F.; Arduini, F. Magnetic Beads
890 Combined with Carbon Black-Based Screen-Printed Electrodes for
891 COVID-19: A Reliable and Miniaturized Electrochemical Immuno-
892 sensor for SARS-CoV-2 Detection in Saliva. *Biosens. Bioelectron.* **2021**,
893 *171*, No. 112686.
- 894 (19) Saatçi, E.; Natarajan, S. State-of-the-Art Colloidal Particles and
895 Unique Interfaces-Based SARS-CoV-2 Detection Methods and
896 COVID-19 Diagnosis. *Curr. Opin. Colloid Interface Sci.* **2021**, *55*,
897 No. 101469.
- 898 (20) Lau, C. S.; Aw, T.-C. SARS-CoV-2 Antigen Testing Intervals:
899 Twice or Thrice a Week? *Diagnostics* **2022**, *12*, 1039.
- 900 (21) Amaral, C.; Antunes, W.; Moe, E.; Duarte, A. G.; Lima, L. M.
901 P.; Santos, C.; Gomes, I. L.; Afonso, G. S.; Vieira, R.; Teles, H. S. S.;
902 Reis, M. S.; da Silva, M. A. R.; Henriques, A. M.; Fevereiro, M.;
903 Ventura, M. R.; Serrano, M.; Pimentel, C. A Molecular Test Based on
904 RT-LAMP for Rapid, Sensitive and Inexpensive Colorimetric
905 Detection of SARS-CoV-2 in Clinical Samples. *Sci. Rep.* **2021**, *11*,
906 No. 16430.
- 907 (22) Xu, N.; Jin, S.; Wang, L. Metal Nanoparticles-Based
908 Nanoplatfoms for Colorimetric Sensing: A Review. *Rev. Anal.
909 Chem.* **2021**, *40*, 1–11.
- 910 (23) Liang, P.; Guo, Q.; Zhao, T.; Wen, C. Y.; Tian, Z.; Shang, Y.;
911 Xing, J.; Jiang, Y.; Zeng, J. Ag Nanoparticles with Ultrathin Au Shell-
912 Based Lateral Flow Immunoassay for Colorimetric and SERS Dual-
913 Mode Detection of SARS-CoV-2 IgG. *Anal. Chem.* **2022**, *94*, 8466–
914 8473.
- 915 (24) Ventura, B. D.; Cennamo, M.; Minopoli, A.; Campanile, R.;
916 Censi, S. B.; Terracciano, D.; Portella, G.; Velotta, R. Colorimetric
917 Test for Fast Detection of SARS-COV-2 in Nasal and Throat Swabs.
918 *ACS Sens.* **2020**, *5*, 3043–3048.
- 919 (25) Han, H.; Wang, C.; Yang, X.; Zheng, S.; Cheng, X.; Liu, Z.;
920 Zhao, B.; Xiao, R. Rapid Field Determination of SARS-CoV-2 by a
921 Colorimetric and Fluorescent Dual-Functional Lateral Flow Immuno-
922 assay Biosensor. *Sens. Actuators, B* **2022**, *351*, No. 130897.
- 923 (26) Yadav, S.; Sadique, M. A.; Ranjan, P.; Kumar, N.; Singhal, A.;
924 Srivastava, A. K.; Khan, R. Sers Based Lateral Flow Immunoassay for
925 Point-of-Care Detection of Sars-Cov-2 in Clinical Samples. *ACS Appl.
926 Bio Mater.* **2021**, *4*, 2974–2995.
- 927 (27) Georgiou, P. G.; Guy, C. S.; Hasan, M.; Ahmad, A.; Richards, S.
928 J.; Baker, A. N.; Thakkar, N. V.; Walker, M.; Pandey, S.; Anderson, N.
929 R.; Grammatopoulos, D.; Gibson, M. I. Plasmonic Detection of
930 SARS-CoV-2 Spike Protein with Polymer-Stabilized Glycosylated
931 Gold Nanorods. *ACS Macro Lett.* **2022**, *11*, 317–322.
- 932 (28) Antiochia, R. Nanobiosensors as New Diagnostic Tools for
933 SARS, MERS and COVID-19: From Past to Perspectives. *Microchim.
934 Acta* **2020**, *187*, No. 639.
- 935 (29) Lew, T. T. S.; Aung, K. M. M.; Ow, S. Y.; Amrun, S. N.;
936 Sutarlie, L.; Ng, L. F. P.; Su, X. Epitope-Functionalized Gold
937 Nanoparticles for Rapid and Selective Detection of SARS-CoV-2 IgG
938 Antibodies. *ACS Nano* **2021**, *15*, 12286–12297.
- 939 (30) Huang, X.; Jain, P. K.; El-Sayed, I. H.; El-Sayed, M. A. Gold
940 Nanoparticles: Interesting Optical Properties and Recent Applications
941 in Cancer Diagnostics and Therapy. *Nanomedicine* **2007**, *2*, 681–693.
- 942 (31) Draz, M. S.; Shafiee, H. Applications of Gold Nanoparticles in
943 Virus Detection. *Theranostics* **2018**, *8*, 1985–2017.
- 944 (32) Hall, W. P.; Ngatia, S. N.; Van Duyne, R. P. LSPR Biosensor
945 Signal Enhancement Using Nanoparticle-Antibody Conjugates. *J.
946 Phys. Chem. C* **2011**, *115*, 1410–1414.
- 947 (33) Mayer, K. M.; Hafner, J. H. Localized Surface Plasmon
948 Resonance Sensors. *Chem. Rev.* **2011**, *111*, 3828–3857.
- 949 (34) Li, M.; Cushing, S. K.; Wu, N. Plasmon-Enhanced Optical
950 Sensors: A Review. *Analyst* **2015**, *140*, 386–406.
- 951 (35) Pramanik, A.; Gao, Y.; Patibandla, S.; Mitra, D.; McCandless,
952 M. G.; Fassero, L. A.; Gates, K.; Tandon, R.; Chandra Ray, P. The
953 Rapid Diagnosis and Effective Inhibition of Coronavirus Using Spike
954 Antibody Attached Gold Nanoparticles. *Nanoscale Adv.* **2021**, *3*,
955 1588–1596.
- 956 (36) Herizchi, R.; Abbasi, E.; Milani, M.; Akbarzadeh, A. Current
957 Methods for Synthesis of Gold Nanoparticles. *Artif. Cells, Nanomed.,
958 Biotechnol.* **2016**, *44*, 596–602.
- 959 (37) Patterson, E. I.; Prince, T.; Anderson, E. R.; Casas-Sanchez, A.;
960 Smith, S. L.; Cansado-Utrilla, C.; Solomon, T.; Griffiths, M. J.;
961 Acosta-Serrano, A.; Turtle, L.; Hughes, G. L. Methods of Inactivation
962 of SARS-CoV-2 for Downstream Biological Assays. *J. Infect. Dis.* **2020**,
963 *222*, 1462–1467.
- 964 (38) Lo, C. W.; Matsuura, R.; Iimura, K.; Wada, S.; Shinjo, A.;
965 Benno, Y.; Nakagawa, M.; Takei, M.; Aida, Y. UVC Disinfects SARS-
966 CoV-2 by Induction of Viral Genome Damage without Apparent
967 Effects on Viral Morphology and Proteins. *Sci. Rep.* **2021**, *11*,
968 No. 13804.
- 969 (39) Loveday, E. K.; Hain, K. S.; Kochetkova, I.; Hedges, J. F.;
970 Robison, A.; Snyder, D. T.; Brumfield, S. K.; Young, M. J.; Jutila, M.
971 A.; Chang, C. B.; Taylor, M. P. Effect of Inactivation Methods on
972 Sars-Cov-2 Virion Protein and Structure. *Viruses* **2021**, *13*, 562.

- 973 (40) Karakuş, E.; Erdemir, E.; Demirbilek, N.; Liv, L. Colorimetric
974 and Electrochemical Detection of SARS-CoV-2 Spike Antigen with a
975 Gold Nanoparticle-Based Biosensor. *Anal. Chim. Acta* **2021**, *1182*,
976 No. 338939.
- 977 (41) Guimarães, T. F.; Vital, I. C. F.; de Sousa, E. G. R.; Boniatti, J.;
978 Bandini, T. B.; Carr, O.; Oliveira, O. N.; Shimizu, F. M.; da Fonseca,
979 L. B.; Viçosa, A. L. Investigation of Chloroquine Resinate Feasibility
980 and In Vitro Taste Masking Evaluation for Pediatric Formulations.
981 *AAPS PharmSciTech* **2022**, *23*, No. 69.
- 982 (42) Bhattarai, K. R.; Kim, H. R.; Chae, H. J. Compliance with Saliva
983 Collection Protocol in Healthy Volunteers: Strategies for Managing
984 Risk and Errors. *Int. J. Med. Sci.* **2018**, *15*, 823–831.
- 985 (43) Peters, R. J. B.; van Bommel, G.; Milani, N. B. L.; den Hertog,
986 G. C. T.; Undas, A. K.; van der Lee, M.; Bouwmeester, H. Detection
987 of Nanoparticles in Dutch Surface Waters. *Sci. Total Environ.* **2018**,
988 *621*, 210–218.
- 989 (44) Zhang, L.; Mazouzi, Y.; Salmain, M.; Liedberg, B.; Boujday, S.
990 Antibody-Gold Nanoparticle Bioconjugates for Biosensors: Synthesis,
991 Characterization and Selected Applications. *Biosens. Bioelectron.* **2020**,
992 *165*, No. 112370.
- 993 (45) Liao, H.; Hafner, J. H. Gold Nanorod Bioconjugates. *Chem.*
994 *Mater.* **2005**, *17*, 4636–4641.
- 995 (46) Harron, D. W. G. Technical Requirements for Registration of
996 Pharmaceuticals for Human Use: The ICH Process. In *The Textbook*
997 *of Pharmaceutical Medicine*; Blackwell Publishing Ltd: Oxford, U.K.,
998 2013; Vol. 1994, pp 447–460. DOI: 10.1002/9781118532331.ch23.
- 999 (47) Johnson, P. B.; Christy, R. W. Optical Constants of the Noble
1000 Metals. *Phys. Rev. B* **1972**, *6*, 4370–4379.
- 1001 (48) Baidya, S.; Hassan, A. M. A Computational Study of COVID-
1002 19 Detection Using Colorimetric Plasmonic Sensors. In *2021 IEEE*
1003 *International Symposium on Antennas and Propagation and USNC-*
1004 *URSI Radio Science Meeting (APS/URSI)*; IEEE, 2021; pp 1731–1732.
1005 DOI: 10.1109/APS/URSI47566.2021.9704523.
- 1006 (49) Minopoli, A.; Scardapane, E.; Acunzo, A.; Campanile, R.; Della
1007 Ventura, B.; Velotta, R. Analysis of the Optical Response of a SARS-
1008 CoV-2-Directed Colorimetric Immunosensor. *AIP Adv.* **2021**, *11*,
1009 No. 065319.
- 1010 (50) Ansar, S. M.; Chakraborty, S.; Kitchens, C. L. PH-Responsive
1011 Mercaptoundecanoic Acid Functionalized Gold Nanoparticles and
1012 Applications in Catalysis. *Nanomaterials* **2018**, *8*, 339.
- 1013 (51) Raman, A.; Jaime, C.; Puentes, V. F. Domain Formation and
1014 Conformational Changes in Gold Nanoparticle Conjugates Studied
1015 Using DPD Simulations. *Langmuir* **2017**, *33*, 14502–14512.
- 1016 (52) Fujiwara, K.; Watarai, H.; Itoh, H.; Nakahama, E.; Ogawa, N.
1017 Measurement of Antibody Binding to Protein Immobilized on Gold
1018 Nanoparticles by Localized Surface Plasmon Spectroscopy. *Anal.*
1019 *Bioanal. Chem.* **2006**, *386*, 639–644.
- 1020 (53) Guvenc, B.; Yesilay, G.; Yavuz, Y.; Yilmaz, B.; Culha, M.
1021 Electrophysiological Effects of Polyethylene Glycol Modified Gold
1022 Nanoparticles on Mouse Hippocampal Neurons. *Heliyon* **2020**, *6*,
1023 No. e05824.
- 1024 (54) Bravin, C.; Amendola, V. Plasmonic Absorption in Antigen-
1025 Induced Aggregated Gold Nanoparticles: Toward a Figure of Merit
1026 for Optical Nanosensors. *ACS Appl. Nano Mater.* **2022**, *5*, 578–586.
- 1027 (55) Tsai, T. C.; Liu, C. W.; Wu, Y. C.; Ondevilla, N. A. P.; Osawa,
1028 M.; Chang, H. C. In Situ Study of EDC/NHS Immobilization on
1029 Gold Surface Based on Attenuated Total Reflection Surface-Enhanced
1030 Infrared Absorption Spectroscopy (ATR-SEIRAS). *Colloids Surf., B*
1031 **2019**, *175*, 300–305.
- 1032 (56) Lee, J.; Zhou, H.; Lee, J. Small Molecule Induced Self-Assembly
1033 of Au Nanoparticles. *J. Mater. Chem.* **2011**, *21*, 16935.
- 1034 (57) Busch, R. T.; Karim, F.; Weis, J.; Sun, Y.; Zhao, C.; Vasquez, E.
1035 S. Optimization and Structural Stability of Gold Nanoparticle-
1036 Antibody Bioconjugates. *ACS Omega* **2019**, *4*, 15269–15279.
- 1037 (58) Ngunjiri, J. N.; Stark, D. J.; Tian, T.; Briggman, K. A.; Garno, J.
1038 C. Immobilization of Proteins on Carboxylic Acid Functionalized
1039 Nanopatterns. *Anal. Bioanal. Chem.* **2013**, *405*, 1985–1993.
- 1040 (59) Sam, S.; Touahir, L.; Salvador Andresa, J.; Allongue, P.;
1041 Chazalviel, J. N.; Gouget-Laemmel, A. C.; De Villeneuve, C. H.;
Moraillon, A.; Ozanam, F.; Gabouze, N.; Djebbar, S. Semiquantitative
Study of the EDC/NHS Activation of Acid Terminal Groups at
Modified Porous Silicon Surfaces. *Langmuir* **2010**, *26*, 809–814.
- (60) Endo, T.; Kerman, K.; Nagatani, N.; Hiepa, H. M.; Kim, D. K.;
Yonezawa, Y.; Nakano, K.; Tamiya, E. Multiple Label-Free Detection
of Antigen-Antibody Reaction Using Localized Surface Plasmon
Resonance-Based Core-Shell Structured Nanoparticle Layer Nano-
chip. *Anal. Chem.* **2006**, *78*, 6465–6475.
- (61) Meng, L.; Yin, J. H.; Yuan, Y.; Xu, N. 11-Mercaptoundecanoic
Acid Capped Gold Nanoclusters as a Fluorescent Probe for Specific
Detection of Folic Acid: Via a Ratiometric Fluorescence Strategy. *RSC*
Adv. **2018**, *8*, 9327–9333.
- (62) Garcia-Hernandez, C.; Freese, A. K.; Rodriguez-Mendez, M. L.;
Wanekaya, A. K. In Situ Synthesis, Stabilization and Activity of
Protein-Modified Gold Nanoparticles for Biological Applications.
Biomater. Sci. **2019**, *7*, 2511–2519.
- (63) Manson, J.; Kumar, D.; Meenan, B. J.; Dixon, D. Polyethylene
Glycol Functionalized Gold Nanoparticles: The Influence of Capping
Density on Stability in Various Media. *Gold Bull.* **2011**, *44*, 99–105.
- (64) Moitra, P.; Alafeef, M.; Dighe, K.; Frieman, M. B.; Pan, D.
Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene
Targeted Antisense Oligonucleotide Capped Plasmonic Nano-
particles. *ACS Nano* **2020**, *14*, 7617–7627.
- (65) da Silva, P. B.; da Silva, J. R.; Rodrigues, M. C.; Vieira, J. A.; de
Andrade, I. A.; Nagata, T.; Santos, A. S.; da Silva, S. W.; da Rocha, M.
C. O.; Bão, S. N.; Moraes-Vieira, P. M.; Proença-Modena, J.; Angelim,
M. K. C.; de Souza, G. F.; Muraro, S. P.; de Barros, A. L. B.; de Souza
Martins, G. A.; Ribeiro-Dias, F.; Machado, G.; Fessel, M. R.;
Chudzinski-Tavassi, A. M.; Ronconi, C. M.; Gonçalves, D.; Curi, R.;
Oliveira, O. N.; Azevedo, R. B. Detection of SARS-CoV-2 Virus via
Dynamic Light Scattering Using Antibody-Gold Nanoparticle
Bioconjugates against Viral Spike Protein. *Talanta* **2022**, *243*,
No. 123355.
- (66) Brandl, D. W.; Mirin, N. A.; Nordlander, P. Plasmon Modes of
Nanosphere Trimers and Quadrumers. *J. Phys. Chem. B* **2006**, *110*,
12302–12310.
- (67) Raikar, U. S.; Tangod, V. B.; Mastiholi, B. M.; Fulari, V. J.
Fluorescence Quenching Using Plasmonic Gold Nanoparticles. *Opt.*
Commun. **2011**, *284*, 4761–4765.
- (68) Zhang, Y.; Fei, W.-W.; Jia, N.-Q. A Facile Method for the
Detection of DNA by Using Gold Nanoparticle Probes Coupled with
Dynamic Light Scattering. *Nanoscale Res. Lett.* **2012**, *7*, No. 564.
- (69) Paulovich, F. V.; Moraes, M. L.; Maki, R. M.; Ferreira, M.;
Oliveira, O. N., Jr.; de Oliveira, M. C. F. Information Visualization
Techniques for Sensing and Biosensing. *Analyst* **2011**, *136*, 1344.
- (70) Neto, M. P.; Paulovich, F. V. Explainable Matrix - Visualization
for Global and Local Interpretability of Random Forest Classification
Ensembles. *IEEE Trans. Visual Comput. Graphics* **2021**, *27*, 1427–
1437.
- (71) Ihsanullah, I.; Bilal, M.; Naushad, M. Coronavirus 2 (SARS-
CoV-2) in Water Environments: Current Status, Challenges and
Research Opportunities. *J. Water Process Eng.* **2021**, *39*, No. 101735.
- (72) Woolf, M. S.; Dignan, L. M.; Scott, A. T.; Landers, J. P. Digital
Postprocessing and Image Segmentation for Objective Analysis of
Colorimetric Reactions. *Nat. Protoc.* **2021**, *16*, 218–238.
- (73) Brinati, D.; Campagner, A.; Ferrari, D.; Locatelli, M.; Banfi, G.;
Cabitza, F. Detection of COVID-19 Infection from Routine Blood
Exams with Machine Learning: A Feasibility Study. *J. Med. Syst.* **2020**,
44, No. 135.